Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MORETriple-action, once-a-day treatment for 7 days for even the most stubborn cases associated with susceptible strains of yeast and bacteria in canines.
LEARN MOREFor treatment of respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella Choleraesuis, Streptococcus…
LEARN MOREFor treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and bovine interdigital phlegmon associated with…
LEARN MORE